Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S2-E19.2 - Patient-Centric Themes At The 4th Global NASH Congress
Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review holistic and patient-centric issues to be covered at the 4th Global NASH Congress.
Keynot…
S2-E19.1 - Non-Invasive Testing Themes at the 4th Global NASH Congress
Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review non-invasive testing themes to be covered at the 4th Global NASH Congress.
Keynote Speake…
S2-E19 - Previewing the 4th Global NASH congress
Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to survey the agenda for the 4th Global NASH Congress.
The 4th Global NASH Congress has presentatio…
S2 E18.3 -- Stephen Harrison and Alina Allen discuss what her work portends for future trials.
Roger Green conducts one-on-one interviews with Stephen Harrison and Alina Allen to explore specific issues regarding new issues and insights for clinical research and drug development …
S2 E18.2 -- How Might We Treat Differently If We Knew Which Cirrhotic Patients Are Likely To Progress?
The group focuses on the patient treatment implications of being able to identify the patients who are at risk of rapid progression, particularly among those with compensated cirrhosis.…
S2 E18.1 -- How Does MR Elastography Help Identify NASH PAtients Who Are Likely To Progress?
Alina Allen shares the results of her recent Clinical Gastroenterology and Hepatology paper on predictive value of MR Elastography in determining likelihood of progress for NASH patient…
S2-E18 - Magnetic Resonance Elastography Predicts Prognosis for NASH patients
Alina Allen of the Mayo Clinic joins the Surfers to discuss her recent publication demonstrating that kPa scores from MR Elastography can predict the course of disease for non-cirrhotic…
S2-E17.3 -- The value of ultrasound and the goals of patient screenin
Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. This conversations starts by questioning the incremental val…
S2-E17.2 — Modeling the relative impact of treating NASH vs. CVD in patients with different fibrosis levels
S2-E17.1 - Questions in Screening: Do Liquid Tests Bring Better Value than Elastography?
Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversation to consider what "efficiency" me…
S2-E17 - New lessons from Leeds: Streamlining Non-Invasive Testing algorithms
Ian Rowe joins the Surfers to discuss more detailed findings from the on-going analyses he and Richard Parker are conducting on abnormal liver tests among patients in Leeds, UK.
In this …
S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to Market
In different ways, …
S2-E16.2 - Future Directions for NASH Cost-Effectiveness Research
In response to…
S2 E16.1 -- How Cost-Effectiveness Research On Widespread NIT Screening In The U.S. Has Evolved
S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment
Mazen Noureddin joins the Surfers to discuss his work determining cost effectiveness of Non-Invasive Testing in Type 2 diabetics and the broader population. The discussion shifts to con…
S2-E15 — Wrapping Up NASH-TAG 2021
Surfing the NASH Tsunami closes the book on NASH-TAG 2021 by considering highlights and major themes of the conference. The conversation focuses on the dramatic increase in disease know…
S2-E14 - NASH-TAG Session 4 Summary: Basic Science and Promising Drugs on the Horizon
Naim Alkhouri and Jörn Schattenberg join Roger and Donna to review the closing session of NASH-TAG 2021, a potpourri of basic science and review of promising drugs earlier in developmen…
S2-E13 - NASH-TAG Session 3 Summary: Trial Designs of the Future and the Future of Diabetes Drugs in NASH
NASH-TAG Co-director Michael Charlton and Ian Rowe join Roger, Louise and Donna to review the morning that Michael himself identified as one of two highlight sessions of NASH-TAG 2021.
T…
S2-E12 - NASH-TAG Session 2 Summary: Innovative Trial Design and Robust Histologic Analyses
Jörn Schattenberg and Naim Alkhouri join the Surfers (including NASH-TAG co-director Stephen Harrison) to review NASH-TAG session to with its focus on innovative trial design and improv…
S2 E11 — NASH-TAG Session 1 summary: Major Drugs in Development and Why Trials Fail
Manal Abdelmalek and Ian Rowe join Roger, Louise and Donna to review the morning that Vlad Ratziu and Michael Charlton both identified as the highlight session of NASH-TAG 2021.
The Fri…